VPC
DNLI icon

Vestal Point Capital’s Denali Therapeutics DNLI Stock Holding History

Vestal Point Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,773,326
Closed -$34M – 78
2026
Q1 		$34M Buy
1,773,326
+1,308,326
+281% +$26M 0.95% 38
2025
Q4 		$7.68M Buy
+465,000
New +$7.85M 0.26% 53
2024
Q3 		– Sell
-500,000
Closed -$11.6M – 74
2024
Q2 		$11.6M Buy
+500,000
New +$9.6M 0.87% 33

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestal Point Capital's DNLI Position: Q2 2026 in Review

Vestal Point Capital sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 1,773,326 shares — an estimated $34M sold.

Vestal Point Capital first reported a position in DNLI in Q2 2024 and held it in 3 quarters. The position peaked at $34M in Q1 2026. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Vestal Point Capital reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 1,773,326 Denali Therapeutics shares in Q2 2026, an estimated $34M.
  • Vestal Point Capital first reported a position in Denali Therapeutics in Q2 2024 and held it in 3 quarters.
  • Vestal Point Capital's Denali Therapeutics position peaked at $34M in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.